U.S. Markets close in 6 hrs 17 mins
  • S&P 500

    3,778.51
    -71.11 (-1.85%)
     
  • Dow 30

    30,430.41
    -506.63 (-1.64%)
     
  • Nasdaq

    13,355.87
    -270.19 (-1.98%)
     
  • Russell 2000

    2,149.86
    -13.41 (-0.62%)
     
  • Crude Oil

    52.27
    -0.34 (-0.65%)
     
  • Gold

    1,838.40
    -12.50 (-0.68%)
     
  • Silver

    24.98
    -0.56 (-2.20%)
     
  • EUR/USD

    1.2070
    -0.0075 (-0.6156%)
     
  • 10-Yr Bond

    1.0130
    -0.0270 (-2.60%)
     
  • Vix

    27.30
    +4.11 (+17.72%)
     
  • GBP/USD

    1.3666
    -0.0010 (-0.0697%)
     
  • USD/JPY

    104.1450
    +0.3890 (+0.3749%)
     
  • BTC-USD

    29,773.80
    -1,937.96 (-6.11%)
     
  • CMC Crypto 200

    598.53
    -41.39 (-6.47%)
     
  • FTSE 100

    6,557.59
    -96.42 (-1.45%)
     
  • Nikkei 225

    28,635.21
    +89.01 (+0.31%)
     

SHAREHOLDER ALERT: ZSAN HPQ GDRX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Zosano Pharma Corporation (NASDAQ:ZSAN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11818&wire=1
Lead Plaintiff Deadline: December 28, 2020
Class Period: February 13, 2017 - September 30, 2020

Allegations against ZSAN include that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE:HPQ)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hp-inc-loss-submission-form-2?prid=11818&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: November 6, 2015 - June 21, 2016

Allegations against HPQ include that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.

GoodRx Holdings, Inc (NASDAQ:GDRX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=11818&wire=1
Lead Plaintiff Deadline: February 16, 2021
Class Period: September 23, 2020 - November 16, 2020

Allegations against GDRX include that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/622418/SHAREHOLDER-ALERT-ZSAN-HPQ-GDRX-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines